Skip to main content

Table 4 Factors associated with 12-month outcomes following cART initiation

From: The effect of adherence to guidelines for initial antiretroviral therapy on 1-year outcomes: a French cohort study

  cART modification before 12 month HIV-RNA <50 copies/mL at 12 month CD4 variation from baseline
Characteristic aOR* P aOR* P aRC* P
cART modification ** ** 0.19 (0.15-0.24) <.001 -68.2 (-84.5;-52.0) <.001
Outside "what-to-start" guidelines 1.90 (1.45-2.49) <.001 0.67 (0.45-1.00) .05 - -
Year of guidelines (ref: 2000)       
2002 0.63 (0.42-0.97) .03 0.96 (0.60-1.53) - 4.4 (-26.2-34.9) -
2004 0.57 (0.37-0.87) .009 1.44 (0.90-2.31) - (14.0-75.5) .004
2006 0.33 (0.22-0.58) <.001 2.07 (1.31-3.28) .002 51.4 (22.2-80.6) .001
2008 0.40 (0.27-0.58) <.001 2.05 (1.32-3.17) .001 35.9 (7.7-64.0) .01
2010 0.40 (0.26-0.62) <.001 1.95 (1.19-3.20) .008 27.6 (-3.9-59.1) -
Male gender 0.76 (0.59-0.96) .02 - - - -
HBV/HCV coinfection - - - - -26.1 (-49.6;-2.6) .03
CDC stage C 1.90 (1.45-2.49) <.001 0.54 (0.40-0.73) <.001 -39.4 (-60.5;-18.3) <.001
HIV-RNA >105 cps/mL - - ** ** 61.0 (44.3-77.7) <.001
  1. Abbreviations: HBV hepatitis B virus, HCV hepatitis C virus, CDC Centers for Disease Control and Prevention, HIV human immunodeficiency virus, aOR adjusted odds ratio, aRC adjusted regression coefficient.
  2. Variables not retained in the final multivariate models: age, HIV risk factor, baseline CD4, delay from HIV diagnosis to cART initiation, adherence to "when-to-start" guidelines.
  3. *Adjusted on the other covariates.
  4. **Covariate not in the model.